Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Phase of Trial: Phase II
Latest Information Update: 06 Mar 2018
At a glance
- Drugs Cabozantinib (Primary) ; Dacarbazine; Temozolomide
- Indications Uveal melanoma
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 28 Feb 2018 Status changed from active, no longer recruiting to completed.
- 09 May 2016 Status changed from recruiting to active, no longer recruiting.